Syndrome  >>  Aptivus (tipranavir)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aptivus (tipranavir) / Boehringer Ingelheim
NCT00097799: Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Approved for marketing
N/A
US
Tipranavir, Ritonavir
Boehringer Ingelheim
HIV Infections
08/05
 
NCT00933205: An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Approved for marketing
N/A
Canada, Europe, RoW
Tipranavir
Boehringer Ingelheim
HIV Infections
06/08
 
NCT00531206: Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed
N/A
65
Europe
Tipranavir, Ritonavir
Boehringer Ingelheim
HIV Infections
01/09
 
NCT00615290: Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Completed
N/A
42
Europe
tipranavir
Boehringer Ingelheim
HIV Infections
05/09
 
NCT00805857: Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort

Withdrawn
N/A
0
NA
Tipranavir
Boehringer Ingelheim
HIV Infections
12/09
 
NCT00976950: A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Completed
N/A
42
Europe
Tipranavir, ritonavir
Boehringer Ingelheim
HIV Infections
07/11
07/11
NCT00062660: Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Approved for marketing
N/A
US, Europe, RoW
Tipranavir
Boehringer Ingelheim
HIV Infections
04/14
04/14

Download Options